Orchestra BioMed
OBIO
23 hedge funds and large institutions have $56.4M invested in Orchestra BioMed in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 9 reducing their positions, and 43 closing their positions.
19.04% less ownership
Funds ownership: 69.84% → 50.8% (-19%)
60% less capital invested
Capital invested by funds: $140M → $56.4M (-$83.5M)
63% less funds holding
Funds holding: 62 → 23 (-39)
78% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 9
91% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 43
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$9.91M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.89M |
| 3 |
RL
RPO LLC
Stamford,
Connecticut
|
+$240K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$149K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$9.35M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$7.97M |
| 3 |
SCM
Saba Capital Management
New York
|
-$7.34M |
| 4 |
AC
Amitell Capital
Singapore
|
-$5.98M |
| 5 |
SC
Sculptor Capital
New York
|
-$5.41M |
OBIO Hedge Fund Activity: Q3 2022 in Review
23 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q3 2022, worth a combined $56.4M — down 60% from $140M a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of OBIO and 4 opened new positions — a net loss of 39 holders — while 9 trimmed existing stakes and 2 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $9.91M. The largest seller was D.E. Shaw & Co, exiting entirely with an estimated $9.35M sold.
- 23 institutional investors held Orchestra BioMed (OBIO) as of Q3 2022, down from 62 in Q2 2022.
- Funds reported $56.4M of Orchestra BioMed stock for Q3 2022, down 60% quarter-over-quarter.
- 4 funds opened new Orchestra BioMed positions in Q3 2022 and 43 closed out, a net change of -39 holders.
- The largest Orchestra BioMed buyer in Q3 2022 was RTW Investments, an estimated $9.91M added.
- The largest Orchestra BioMed seller in Q3 2022 was D.E. Shaw & Co, an estimated $9.35M sold.
Based on aggregated 13F filings for Q3 2022.